Abstract
Fabry disease (FD) is a lysosomal storage disorder, which develops due to a deficiency in the hydrolytic enzyme, α-galactosidase A (α-Gal A). Alpha-Gal A hydrolyzes glycosphingolipid globotriaosylceramide (Gb3), and an α-Gal A deficiency leads to Gb3 accumulation in tissues and cells in the body. This pathology is likely to involve multiple systems, but it is generally considered to affect primarily vascular endothelium. In this study, we investigated mutations in the GLA gene, which encodes α-Gal A, in Mexican families with FD. We included seven probands with FD that carried known mutations. We analysed pedigrees of the probands, and performed molecular screening in 65 relatives with the potential of carrying a GLA mutation. Five mutations (P40S, IVS4 +4, G328V, R363H, R404del) were detected in seven unrelated Mexican families with the classic FD phenotype. Of the 65 relatives examined, 42 (64.6%) had a GLA gene mutation. In summary, among seven Mexican probands with FD, 65 relatives were at risk of carrying a known GLA mutation, and molecular screening identified 42 individuals with the mutation. Thus, our findings showed that it is important to perform molecular analysis in families with FD to detect mutations and to provide accurate diagnoses for individuals that could be affected.
This is a preview of subscription content, log in via an institution to check access.
Explore related subjects
Discover the latest articles and news from researchers in related subjects, suggested using machine learning.References
Becerra K., Ríos-González B., Gutiérrez-Amavizca B. E. and Figuera L. 2012 Manifestaciones of talmológicas de enfermedad de Fabry en pacientes mexicanos. Arch. Soc. Esp. Oftalmol. 87, 373–375.
Blaydon D., Hill J. and Winchester B. 2001 Fabry disease: 20 novel GLA mutations in 35 families. Hum. Mutat. 18, 459.
Bono C., Nuzzo D., Albeggiani G., Zizzo C., Francofonte D., Iemolo F. et al. 2011 Genetic screening of Fabry patients with EcoTILLING and HRM technology. BMC Res. Notes 6, 323.
Desnick R. J. and Wasserstein M. P. 2001 Fabry disease: clinical features and recent advances in enzyme replacement therapy. Adv. Nephrol. Necker. Hosp. 31, 317–313.
Desnick R. J. and Brady R. O. 2004 Fabry disease in childhood . J. Pediatr. 144, S20–S26.
Eng C. M., Fletcher J., Wilcox W. R., Waldek S., Scott C. R., Sillence D. O. et al. 2007 Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J. Inherit. Metab. Dis. 30, 184–192.
Ferri L., Guido C., la Marca G., Malvagia S., Cavicchi C. and Fiumara A. 2012 Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene. Clin. Genet. 8, 224–233.
Gal A. 2010 Molecular genetics of Fabry disease and genotype–phenotype correlation. In: Fabry disease (ed. D. Elstein, G. Altarescu and M. Beck), chapter 1, pp. 3–19. Springer, Dordrecht, Heidelberg, London.
Gutiérrez-Amavizca B. E., Orozco-Castellanos R., Padilla-Gutiérrez J. R., Valle Y. and Figuera L. E. 2014 Pedigree analysis of Mexican families with Fabry disease as a powerful tool for identification of heterozygous females. Genet. Mol. Res. 13, 6752–6758.
Koide T., Ishiura M., Iwai K., Inoue M., Kaneda Y., Okada Y. et al. 1990 A case of Fabry’s disease in a patient with no alpha-galactosidase A activity caused by a single amino acid substitution of Pro-40 by Ser. FEBS Lett. 259, 353–356.
Miller S., Dykes D. and Polesky F. 1998 A simple salting out procedure for extracting DNA for human nucleated cells. Nucleic Acids Res. 16, 1215.
Pastores G. M. and Lien Y. H. 2002 Biochemical and molecular genetic basis of Fabry disease. J. Am. Soc. Nephrol. 13, S130–S133.
Ramos-Kuri M., Olvera D., Morales J. J., Rodriguez-Espino B. A., Lara-Mejía A., De Los Ríos D. et al. 2014 Clinical, histological and molecular characteristics of Mexican patients with Fabry disease and significant renal involvement. Arch. Med. Res. 45, 257–262.
Shabbeer J., Yasuda M., Luca E. and Desnick R. J. 2002 Fabry disease: 45 novel mutations in the alpha-galactosidase A gene causing the classical phenotype. Mol. Genet. Metab. 76, 23–30.
Shabbeer J., Yasuda M., Benson S. D. and Desnick R. J. 2006 Fabry disease: identification of 50 novel alpha-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations. Hum. Genomics 2, 297–309.
Topaloglu A. K., Ashley G. A., Tong B., Shabbeer J., Astrin K. H., Eng C. M. and Desnick R. J. 1999 Twenty novel mutations in the alpha-galactosidase A gene causing Fabry disease. Mol. Med. 5, 806–811.
Wang R. Y., Lelis A., Mirocha J. and Wilcox W. R. 2007 Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet. Med. 9, 34–35.
www.ensembl.org, GLA gene. European Bioinformatics Institute/Wellcome Trust Sanger Institute, May 2014.
Acknowledgements
We thank the Consejo Nacional de Ciencia y Tecnologa (CONACYT) for the scholarship awarded to B. E. Gutirrez-Amavizca during her doctoral study.
Author information
Authors and Affiliations
Corresponding author
Additional information
Corresponding editor: S. Ganesh
[Gutiérrez-Amavizca B. E., Gal A., Ortíz-Orozco R., Orth U., Prado Montes De Oca E., Gutiérrez-Amavizca J. P. and Figuera L. E. 2017 Mutational analysis of the GLA gene in Mexican families with Fabry disease. J. Genet. 96, xx–xx]
Rights and permissions
About this article
Cite this article
GUTIÉRREZ-AMAVIZCA, B.E., GAL, A., ORTÍZ-OROZCO, R. et al. Mutational analysis of the GLA gene in Mexican families with Fabry disease. J Genet 96, 161–164 (2017). https://doi.org/10.1007/s12041-017-0744-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12041-017-0744-4